Novel NPY2R agonist BI 1820237 provides synergistic anti-obesity efficacy when combined with the GCGR/GLP-1R dual agonist survodutide

Summary: Objective: Nutrient-stimulated gut hormone peptide YY3–36 (PYY3–36) selectively activates the neuropeptide Y2 receptor (NPY2R) and reduces energy intake in humans. We describe the discovery and pharmacology of the long-acting NPY2R agonist BI 1820237 and its potential bodyweight-lowering e...

Täydet tiedot

Bibliografiset tiedot

Päätekijät:	Robert Augustin, Anouk Oldenburger, Tamara Baader-Pagler, Tina Zimmermann, Jens Borghardt, Jacob Hecksher-Sørensen, Angela Baljuls, Wolfgang Reindl, Bartlomiej Krawczyk, Eric Martel, Albert Brennauer, Stefan Peters, Achim Grube, Lise Biehl Rudkjaer, Peter Haebel
Aineistotyyppi:	Artigo
Kieli:	Inglês
Julkaistu:	Elsevier 2025-09-01
Sarja:	Molecular Metabolism
Aiheet:	PYY3–36 NPY NPY2R BI 1820237 Survodutide Obesity
Linkit:	http://www.sciencedirect.com/science/article/pii/S2212877825001127
Tagit:	Lisää tagi Ei tageja, Lisää ensimmäinen tagi!